Compugen - Utang jangka cendhak perusahaan CGEN

Compugen Ltd. (CGEN) lacks predictable cash flows, as the drug testing stage precludes regular income and the budget relies on investments and grants. The business focuses on developing agents that activate the body's own defenses to fight tumors. A licensing model for open formulas to industry behemoths via IT algorithms minimizes market risks, with the indicator standing at 0.00, as reflected in the price action shown below.

Investors seek a balance between market value and the actual scale of the business. This indicator measures the volume of liabilities maturing within one year, identifying the risk of cash flow gaps. For Compugen Ltd. (CGEN), controlling these funds is critical when financing energy-efficient IT systems and sustainable drug modeling. The dynamics of short-term financial liabilities allow for an assessment of the accuracy of payment calendar execution. Analyzing the curve helps forecast the stability of operating capital.